Concepedia

Beth Overmoyer

BO

Statistics

Publications

92

Citations

8.6K

H-Index

41

Active since

1987

Affiliations

Dana-Farber Cancer Institute(Current)

Brigham and Women's Hospital

Harvard University

Massachusetts General Hospital

Dana-Farber Brigham Cancer Center

Beth Overmoyer is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

1987–2025

92

Publications

92

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

Kathy D. Miller, Linnea Chap, Frankie A. Holmes et al. · Journal of Clinical Oncology · 2005 · 1.3K citations · Full text

, , +17

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

Sara M. Tolaney, William T. Barry, Chau T. Dang et al. · New England Journal of Medicine · 2015 · 748 citations · Full text

, , +17

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Howard A. Burris, Herbert I. Hurwitz, Elizabeth Claire Dees et al. · Journal of Clinical Oncology · 2005 · 625 citations · Full text

, , +17

Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer

Stephen E. Jones, John K. Erban, Beth Overmoyer et al. · Journal of Clinical Oncology · 2005 · 547 citations · Full text

, , +14

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

Afshin Dowlati, Kelly M. Robertson, Matthew M. Cooney et al. · PubMed · 2002 · 406 citations

, , +17

1–5 of 92